New trial aims to cure HER2+ breast cancer with smart, adaptive therapy
NCT ID NCT07459673
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a personalized approach for people with HER2+ metastatic breast cancer. Doctors use ctDNA blood tests and imaging to decide when to step up or down treatments, including targeted drugs and local therapies, to achieve long-term remission. The goal is to see if this strategy can lead to lasting remission and possibly a cure for some participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fam-trastuzumab deruxtecan-nxki (T-DXd) and pertuzumab
What this could lead to
If successful, this approach could lead to long-lasting remission and possibly cure for some people with HER2+ metastatic breast cancer by personalizing treatment and preventing brain metastases.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The treatment involves multiple drugs and procedures, which can cause side effects, and the personalized strategy may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••